Skip to main
SPRB

SPRB Stock Forecast & Price Target

SPRB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spruce Biosciences is a clinical-stage biopharmaceutical company with a promising pipeline of product candidates aimed at addressing rare endocrine disorders. Their lead candidate, TA-ERT, has shown strong results in reducing biomarkers and preserving cognitive outcomes in patients with MPS IIIB, and recent FDA interactions have confirmed the potential for accelerated approval. With fast track, breakthrough therapy, and orphan drug designations, and a potential peak sales of over $150 million, Spruce Biosciences is well poised for success in the ultra-rare disease market.

Bears say

Spruce Biosciences is currently overvalued, with a 12-month price objective of $220 per share. The company's high risk factors include potential delays and rejections for FDA approval, as well as potential issues with commercial success and competition in the market. With an estimated total enterprise value of $236M and a total firm value of $280M, the stock may not be a sound investment choice in the long term.

SPRB has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spruce Biosciences Inc (SPRB) Forecast

Analysts have given SPRB a Buy based on their latest research and market trends.

According to 6 analysts, SPRB has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spruce Biosciences Inc (SPRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.